Stock Market News
Latest financial news · Updated Jun 24, 2026
UnitedHealth Group stock slides after Berkshire Hathaway exits position in the health insurer
The panelists generally agree that Berkshire Hathaway's sale of its entire UnitedHealth stake is likely a portfolio rebalancing move rather …
Weekly Stock List
The panel consensus is that Argus' Focus List lacks sufficient data for investors to make informed decisions, with high turnover …
Kioxia plans U.S. ADS listing amid AI memory chip boom
Panelists are divided on Kioxia's U.S. ADS listing and Q2 guidance. While some see it as a 'sell the news' …
What Makes Rayonier (RYN) an Inflation Hedge Investment?
The panelists generally agree that the RYN-PotlatchDeltic merger creates a larger timberland REIT with potential for asset sales and buybacks, …
Here’s Why CNH Industrial N.V. (CNH) Surged in Q1
The panel's net takeaway is that CNH Industrial's stock is at risk due to persistent margin pressure, structural pricing power …
Gold at $4,500 an ounce has everyday Americans grabbing shovels — and some are making tens of thousands
The panel consensus is that the romanticization of amateur gold prospecting is a distraction from the real market drivers of …
NextEra Energy to acquire Dominion in $66.8 billion deal
The panel is divided on the $66.8 billion merger between NEE and D, with concerns about regulatory risks, integration challenges, …
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx's progress on KETAFREE and NRX-100 is encouraging, but the company faces significant financial and operational challenges, including high cash …
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
The panel's discussion on Immunome (IMNM) highlights high execution risk, with a narrow focus on Varegacestat's success in a small, …
Is Legacy Education (LGCY) Emerging as a Winner in Healthcare Education?
The panel consensus is bearish on LGCY, citing lack of revenue and enrollment data, regulatory risks, and thin institutional sponsorship.
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum
The panel consensus is bearish on NeurAxis (NRXS), citing extreme illiquidity, high execution risk, and uncertainty around reimbursement translating into …
Under pressure: Tracking the pain in G7 government debt
The panel agrees that high debt-to-GDP ratios and rising yields pose significant risks, with the key concern being the potential …